Specialty drugs and advanced infusions—including CAR-T, bispecifics, and autoimmune therapies—are rapidly moving beyond the hospital.
For biopharma, this shift is critical to payer alignment and commercial success. For providers, it’s an opportunity to expand oncology and specialty services while keeping patients closer to home.
Join Current Health leaders, Chris McGhee, CEO and Dr. Matt Wilkes, CMO as they share evidence, real-world models, and operational strategies for safely scaling specialty therapy delivery in outpatient and community settings.
Key Takeaways
- What REMS removal and shortened monitoring windows mean for delivery models
- How infrastructure and protocols enable safety at scale
- Why payer-ready outpatient pathways are now central to commercial adoption
- Practical steps for providers expanding specialty therapy services
Reserve your spot to learn how specialty therapies can be delivered safely, scalably, and closer to patients.